Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20377316 | 0.79 | — | — | |
| SCHEMBL13685915 | 0.72 | — | — | |
| SCHEMBL13055305 | 0.71 | CA12 (0.40) | CA12CA1CA2CA9 | |
| SCHEMBL18405792 | 0.69 | GLA (0.39) | CA12CA1CA2CA9 | |
| SCHEMBL14000571 | 0.69 | CA12 (0.39) | CA12CA1CA2CA9 | |
| SCHEMBL14000536 | 0.69 | CA12 (0.39) | CA12CA1CA2CA9 | |
| SCHEMBL18405793 | 0.66 | GLA (0.36) | CA12CA1CA2CA9 | |
| SCHEMBL4890325 | 0.64 | — | — | |
| SCHEMBL10002291 | 0.60 | CA12 (0.56) | CA12CA1CA2CA9 | |
| SCHEMBL2079547 | 0.59 | GLA (0.58) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10456405-B2 | Nitric oxide-releasing prodrug molecule of substituted quinazolines | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2019-10-29 | — | — | US | disclosed |
| US-20180250305-A1 | NITRIC OXIDE-RELEASING PRODRUG MOLECULE | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2018-09-06 | — | — | US | disclosed |
| EP-3348548-A1 | NITRIC OXIDE-RELEASING PRODRUG MOLECULE | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2018-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10456405-B2 | Nitric oxide-releasing prodrug molecule of substituted quinazolines | PTGIS, NOS1, NOS2 | CA12 4502/4885CA1 4155/4885CA2 1178/4885 |
| US-20180250305-A1 | NITRIC OXIDE-RELEASING PRODRUG MOLECULE | NOS1, NOS2, PTGIS | CA12 4248/4885CA1 3523/4885CA2 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.